Drug Sponsors

Northwell Health, GE Ventures partner on bioelectronic medicine

Thursday, February 23, 2017

Northwell Health‘s Feinstein Institute for Medical Research has announced a strategic alliance with GE Ventures to support the Feinstein’s Center for Bioelectronic Medicine (CBEM). With this investment, the Feinstein Institute will continue its work in discovering, developing and commercializing new diagnostic and therapeutic solutions in bioelectronic medicine for a wide range of acute and chronic diseases and injuries, including neurodegenerative diseases, cancer, diabetes and hypertension.      

[Read More]

Integra LifeSciences to acquire the Codman Neurosurgery Business for $1.04B in Cash

Thursday, February 16, 2017

Integra LifeSciences, a global provider of medical technology, has made a binding offer to acquire the Johnson & Johnson Codman Neurosurgery business for a price of $1.045 billion in cash. Codman Neurosurgery offers a portfolio of devices focused on advanced hydrocephalus, neuro-critical care and operative neurosurgery. If the binding offer is accepted, upon closing, Integra will be a global provider of neurosurgical products.

[Read More]

PixarBio investors launch lawsuit

Wednesday, February 1, 2017

Lawsuit for Investors in shares of PixarBio announced by Shareholders Foundation. The Shareholders Foundation lawsuit was filed on behalf of certain purchasers of shares of PixarBio over alleged Securities Laws Violations by PixarBio.

[Read More]

Novo Nordisk partners for type 2 diabetes, to launch new research center

Tuesday, January 31, 2017

University of Oxford and Novo Nordisk has announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research center on the premises of the University of Oxford.

[Read More]

Zymeworks opens state-of-the-art lab facility

Monday, January 30, 2017

Zymeworks, a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, has opened a state-of-the-art, 10,000 square foot laboratory facility in Vancouver, Canada.

[Read More]

Endo restructures, cuts 90 jobs

Friday, January 27, 2017

Endo International announced that as part of its comprehensive organizational review, it has initiated a restructuring program. These restructuring actions primarily relate to the company’s corporate functions and branded pharmaceutical R&D functions in Malvern, PA, and Chestnut Ridge, NY. The restructuring program will better align these parts of our organization in size and scope with the company’s recently restructured Generics and U.S Branded Pharmaceutical business units. In addition to realizing greater efficiencies, these actions are expected to provide corresponding cost savings. Endo expects to invest a portion of these cost savings in the company’s core product franchises and new product development programs for both the Branded and Generics business segments. 

[Read More]